论文部分内容阅读
一种以分子为作用目标的治癌药物名为 imatinib mesylate（Gleevec,Glivec）的药物在治疗慢性脊髓性白血病方面比较成功,这种成功具有一定的里程碑意义。该药物是设计以bcr—abl为作用目标的,这是一种存在于癌细胞中的异常蛋白。在其进入美国市场以来的10个月里,该药物的表现足以说明,以分子为作用目标的药物今后很有希望。在本期《自然》杂一上,Alison Abbott对这种药物以及其他先进方法在癌症治疗和诊断方面的前景作了分析。封面图片:人类结肠癌细胞。伽马射线暴GRB01121的余辉的X-射线光谱从红移值高达4.7的这样的宇宙距离来看,伽
A success of molecularly targeted cancer drug called imatinib mesylate (Gleevec, Glivec) has proven to be a milestone in the success of treating chronic spinal cord leukemia. The drug is designed to target bcr-abl, an aberrant protein found in cancer cells. In the 10 months since it entered the U.S. market, the performance of this drug is sufficient to show that the molecularly targeted drug is promising in the future. In this issue of “Nature,” Alison Abbott analyzes the prospect of this drug and other advanced methods in cancer treatment and diagnosis. Cover image: Human colon cancer cells. Gamma Ray Burst GRB01121 Afterglow X-ray Spectroscopy From the redshift value of up to 4.7 such cosmic distances, the gamma